Rodman & Renshaw analyst Mike King initiated coverage of Jasper Therapeutics (JSPR) with a Buy rating and $17 price target
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Briquilimab’s Robust Efficacy and Favorable Safety in Urticaria Indicate Strong Upside for Jasper Therapeutics and Support a Buy Rating
- Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria
- Jasper Therapeutics reports updated data from briquilimab studies
- Maintaining Hold on Jasper: Awaiting Critical BEACON CSU Data to Resolve Clinical and Execution Uncertainty
- Jasper Therapeutics announces leadership transition and briquilimab update